Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is trading lower after the company reported data from the Phase 1b study evaluating ...

Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Nuvectis Pharma, Inc. ( (NVCT) ) has released its Q3 earnings. Here is a breakdown of the information Nuvectis Pharma, Inc. presented to its ...

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Stock analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Nuvectis Pharma in a report released on Tuesday, November 5th.

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ...

About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet ...

Michael J. Carson, Vice President of Finance at Nuvectis Pharma, Inc. (NASDAQ:NVCT), recently sold a portion of his holdings in the company. According to a recent SEC filing, Carson sold 2,755 ...

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company ...

In a recent move that signals confidence in Nuvectis Pharma, Inc. (NASDAQ:NVCT), CEO and Chairman Ron Bentsur has increased his stake in the company through the purchase of ...